Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 12, 2019 - Issue
Submit an article Journal homepage
97
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Assessment of macrophage migration inhibitory factor in patients with verruca vulgaris

Neveen Emad Sorour1 Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Benha Univesity, Benha, Egypt
,
Ahmed Mohamed Hamed1 Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Benha Univesity, Benha, EgyptCorrespondence[email protected]
,
Hala Abd-El Mageed Tabl2 Department of Medical Microbiology and Immunology, Faculty of Medicine, Benha Univesity, Benha, Egypt
&
Amira Abd-El Aziz Ahmed1 Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Benha Univesity, Benha, Egypt
Pages 591-595 | Published online: 22 Aug 2019

References

  • Vali A, Ferdowsi F. Evaluation of the efficacy of 50% citric acid solution in plane wart treatment. Indian J Dermatol. 2007;52:96–98. doi:10.4103/0019-5154.33287
  • Medzhitov R, Janeway CAJ. Immunity: the virtues of a non- clonal system of recognition. Cell. 1997;91:295–298. doi:10.1016/s0092-8674(00)80412-29363937
  • Stanley MA. Immune responses to human papilloma viruses. Indian J Med Res. 2009;130:266–276.19901436
  • Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 1966;153:80–82. Quoted from Bezdek et al., 2018. doi:10.1126/science.153.3731.805938421
  • Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791–800. doi:10.1038/nri120014502271
  • Bloom J, Metz C, Nalawade S, et al. Identification of iguratimod as an inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing potential. J Biol Chem. 2016;291:26502–26514. doi:10.1074/jbc.M116.74332827793992
  • Brocks T, Fedorchenko O, Schliermann N, et al. Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin. Faseb J. 2016;31:526–543. doi:10.1096/fj.201600860R27825106
  • Bernhagen J, Krohn R, Lue H, et al. MIF is a non -cognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13:587–596. doi:10.1038/nm156717435771
  • Tillmann S, Bernhagen J, Noels H. Arrest functions of the MIF Ligand/Receptor axes in Atherogenesis. Front Immunol. 2013;4:115. doi:10.3389/fimmu.2013.0011523720662
  • Marinho CR, Nunez-Apaza LN, Martins-Santos R, et al. IFN-gamma, but not nitric oxide or specific IgG, is essential for the in vivo control of low-virulence sylvio x10/4 trypanosoma cruzi parasites. Scand J Immunol. 2007;66:297–308. doi:10.1111/j.1365-3083.2007.01958.x17635807
  • Roger T, Schlapbach LJ, Schneider A, et al. Plasma levels of MIF and D-Dopachrome Tautomerase show a highly specific profile in early life. Front Immunol. 2017;8:26. doi:10.3389/fimmu.2017.0002628179905
  • Almalak MK, Abdulhussein H, Alhamdi KI. Viral skin warts: clinical and histopathological characterization. J Pharm Biol Chem Sci. 2014;5:1556–1571.
  • Kindt N, Descamps G, Lechien JR, et al. Involvement of HPV infection in the release of macrophage migration inhibitory factor in head and neck squamous cell carcinoma. J Clin Med. 2019;8:75. doi:10.3390/jcm8010075
  • Shi X, Leng L, Wang T, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006;25:595–606. doi:10.1016/j.immuni.2006.08.02017045821
  • Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by MIF: regulatory role in cell proliferation and glucocorticoid action. J Biol Chem. 1999;18:18100–18106. doi:10.1074/jbc.274.25.18100
  • Baugh JA, Donnelly SC. MIF a neuroendocrine modulator of chronic inflammation. J Endocrinol. 2003;179:15–23. doi:10.1677/joe.0.179001514529561
  • Tuschil A, Lam C, Haslberger A, Lindley I. Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation. J Invest Dermatol. 1992;99:294–298. doi:10.1111/1523-1747.ep126166341512465
  • Xu X, Wang B, Ye C, et al. Overexpression of macrophage migration-inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett. 2008;261:147–157. doi:10.1016/j.canlet.2007.11.02818171602
  • He XX, Chen K, Yang J, et al. Macrophage migration-inhibitory factor promotes colorectal cancer. Mol Med. 2009;15:1–10. doi:10.2119/molmed.2008.0010719009023
  • Kindt N, Journe F, Laurent G, Saussez S. Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets. Oncol Lett. 2016;12:2247–2253. doi:10.3892/ol.2016.492927698786
  • Bezdek S, Leng L, Busch H, et al. Macrophage Migration Inhibitory Factor (MIF) drives murine psoriasiform dermatitis. Front Immunol. 2018;9:2262. doi:10.3389/fimmu.2018.0226230333830
  • Babu SN, Chetal G, Kumar S. Macrophage Migration Inhibitory Factor: a potential marker for cancer diagnosis and therapy. Asian Pac J Cancer Preview. 2012;13:1737–1744. doi:10.7314/APJCP.2012.13.5.1737
  • El Hamd MA, Assaf NA, Nada EA. Possible role of interleukin-17 and macrophage migration inhibitory factor in cutaneous warts. J Cosmet Dermatol. 2018;17:1250–1253. doi:10.1111/jocd.1235529250927

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.